Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK)
申请人:CHEN Han-Min
公开号:US20140303112A1
公开(公告)日:2014-10-09
The present invention relates to a method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) and the use of the compounds in the prevention or treatment of disease, including pre-diabetes, type 2 diabetes, syndrome X, metabolic syndrome and obesity.
PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID
申请人:Lee Jong-Ook
公开号:US20110178031A1
公开(公告)日:2011-07-21
The present invention provides a novel class of peptide nucleic acid derivatives, which show good cell penetration and strong binding affinity for nucleic acid.
本发明提供了一类新型的肽核酸衍生物,它们具有良好的细胞穿透性和对核酸的强结合亲和力。
Shape Memory Polymers
申请人:Anthamatten Mitchell L.
公开号:US20110251364A1
公开(公告)日:2011-10-13
The present disclosure relates to Shape Memory Polymers (SMP's) comprising function groups that allow the polymers to be elastically deformed, utilized in the elastically deformed state, and subsequently returned to the original polymorphic shape.
O2-Arylated or O2-glycosylated 1-substituted diazen-1-ium-1,2-diolates and O2-substituted 1- (2-carboxylato)pyrrolidin-1-yl diazen-1-ium-1,2-diolates
申请人:The United States
Government
Office of Technoloy Transfer
公开号:EP1439187A1
公开(公告)日:2004-07-21
Diazeniumdiolates, wherein the N1 position is substituted by an inorganic or organic moiety and the O2-oxygen is bound to a substituted or unsubstituted aromatic group, are provided. Also provided are O2-glycosylated 1-substituted diazen-1-ium-1,2-diolates (O2-glycosylated diazeniumdiolates) and O2-substituted 1-[(2-carboxylato)pyrrolidin-1-y]diazen-1-ium-1,2-diolates (1-[(2-carboxylato)öyrrolidin-1-yl]diazeniumdiolates). The O2-aryl diazeniumdiolates are stable with respect to the hydrolytic generation of nitric oxide in neutral to acidic solutions and generate nitric oxide in basic or nucleophilic environments or microenvironments. Also provided are compositions, including pharmaceutical compositions, comprising such compounds and methods of using such compounds.